Commentary · 21 Feb 2026
Conference abstractPublished 26 Sep 2016
Toxin-based targeted therapeutics for the treatment of solid tumors
San Raffaele Scientific Institute, Italy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The toxicity of conventional chemotherapeutic drugs owing to non-specific activity, as well as the development of multidrug resistance, support the need to find new treatments, according to the distinctiveness of the molecular profile of tumor cells and tumor environment. In the last decades, the use of targeted toxins has shown promising results in pilot preclinical and clinical studies, due to their ability to cope with cancer cells heterogeneity and off-target activity. In the current study, we have developed a chimera consisting of the plant toxin saporin (SAP) fused to the amino-terminal fragment (ATF) of human urokinase-type plasminogen activator (uPA), the latter previously demonstrated to specifically deliver payloads to uPA receptor (uPAR) overexpressing cells. ATF-SAP was produced in the P. pastoris yeast optimized as host for production of toxic SAP chimeras. The cytotoxicity of ATF-SAP, evaluated in vitro on different human solid and hematological tumor cell lines and compared to SAP alone, was found to correlate with the expression of the target antigen. Notably, we show that ATF-SAP activity is proportionally confined to uPAR-expressing malignant cells and that its cytotoxicity is unambiguously due to the activity of saporin, as a catalytically inactive mutant (ATF-SAP KQ) failed to exert any effect. The present data suggest that the employment of ATF-SAP can be considered a suitable toxin-based anti-cancer therapeutic option. The assessment of ATF-SAP activity on uPAR overexpressing patient-derived samples and on human tumor xenograft mouse models derived thereof will provide key informations for its future development as anticancer agent.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Stefania Zuppone”
